Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing
Purpose: Although CHEK2 is a well-established cancer gene, questions remain including whether risks vary substantially between different variants and whether biallelic carriers have higher risks than heterozygotes. We report on a cohort of individuals with CHEK2 pathogenic and likely pathogenic variants (collectively, PV) in order to better characterize this gene.
Methods: We retrospectively queried samples submitted for multi-gene hereditary cancer testing to identify individuals with CHEK2 PVs and assessed differences in phenotypes among various genotypes.
Results: CHEK2 PVs were identified in 2508 individuals, including 32 individuals with biallelic CHEK2 PVs. Breast (female, 59.9% and male, 11.8%), prostate (20.1%), and colorectal (3.5%), were among the most frequently reported cancers. Select missense PVs showed similar cancer prevalence to truncating PVs while some others showed lower prevalence. No significant differences were observed between biallelic carriers and heterozygotes.
Conclusions: Our data support that some, but not all, CHEK2 missense PVs demonstrate lower cancer prevalence; further studies are needed to continue characterizing possible variant specific risks. In addition, biallelic CHEK2 PVs do not appear to be associated with a more severe phenotype than single CHEK2 PVs. Furthermore, co-occurrences with PVs in other cancer risk genes are common among CHEK2 heterozygotes and often warrant additional management.
PSMB8 Antibody |
|||
| 1-CSB-PA775839 | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
|||
PSMB8 Conjugated Antibody |
|||
| C43134 | SAB | 100ul | EUR 476.4 |
PSMB8 Polyclonal Antibody |
|||
| A73468 | EpiGentek |
|
|
PSMB8 Antibody, HRP conjugated |
|||
| 1-CSB-PA018886LB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
PSMB8 Antibody, FITC conjugated |
|||
| 1-CSB-PA018886LC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
PSMB8 Antibody, Biotin conjugated |
|||
| 1-CSB-PA018886LD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
Monoclonal PSMB8 Antibody, Clone: 1A5 |
|||
| AMM02864G | Leading Biology | 0.1ml | EUR 633.6 |
|
Description: A Monoclonal antibody against Human PSMB8. The antibodies are raised in Mouse and are from clone 1A5. This antibody is applicable in WB and IHC, ICC, E |
|||
Psmb8/ Rat Psmb8 ELISA Kit |
|||
| ELI-15652r | Lifescience Market | 96 Tests | EUR 1063.2 |
Proteasome subunit beta type-8 (PSMB8) Antibody |
|||
| 20-abx211178 | Abbexa |
|
|
Proteasome subunit beta type-8 (PSMB8) Antibody |
|||
| 20-abx211851 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx141396 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx114776 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx028154-400ul | Abbexa | 400 ul | EUR 627.6 |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx028154-80l | Abbexa | 80 µl | EUR 343.2 |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx006453 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx011689-100ul | Abbexa | 100 ul | EUR 493.2 |
Monoclonal PSMB8 Antibody (monoclonal) (M01), Clone: 1B3 |
|||
| AMM03954G | Leading Biology | 0.1mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human PSMB8 (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 1B3. This antibody is applicable in WB, IHC and IF, IP, E |
|||
PSMB8 siRNA |
|||
| 20-abx930156 | Abbexa |
|
|
PSMB8 siRNA |
|||
| 20-abx930157 | Abbexa |
|
|
PSMB8 siRNA |
|||
| 20-abx904317 | Abbexa |
|
|
PSMB8 Rabbit pAb |
|||
| A7340-100ul | Abclonal | 100 ul | EUR 369.6 |
PSMB8 Rabbit pAb |
|||
| A7340-200ul | Abclonal | 200 ul | EUR 550.8 |
PSMB8 Rabbit pAb |
|||
| A7340-20ul | Abclonal | 20 ul | EUR 219.6 |
PSMB8 Rabbit pAb |
|||
| A7340-50ul | Abclonal | 50 ul | EUR 267.6 |
PSMB8 Blocking Peptide |
|||
| BF0434-BP | Affbiotech | 1mg | EUR 234 |
PSMB8 protein (His tag) |
|||
| 80R-2608 | Fitzgerald | 100 ug | EUR 386.4 |
|
Description: Purified recombinant PSMB8 protein |
|||
Canine PSMB8 ELISA KIT |
|||
| ELI-15651d | Lifescience Market | 96 Tests | EUR 1113.6 |
Rat PSMB8 shRNA Plasmid |
|||
| 20-abx984734 | Abbexa |
|
|
Human PSMB8 shRNA Plasmid |
|||
| 20-abx953843 | Abbexa |
|
|
Mouse PSMB8 shRNA Plasmid |
|||
| 20-abx971337 | Abbexa |
|
|
PSMB8 Recombinant Protein (Rat) |
|||
| RP222629 | ABM | 100 ug | Ask for price |
PSMB8 Recombinant Protein (Mouse) |
|||
| RP165287 | ABM | 100 ug | Ask for price |
PSMB8 Recombinant Protein (Human) |
|||
| RP085356 | ABM | 100 ug | Ask for price |
Psmb8 ORF Vector (Rat) (pORF) |
|||
| ORF074211 | ABM | 1.0 ug DNA | EUR 607.2 |
PSMB8 ORF Vector (Human) (pORF) |
|||
| ORF028453 | ABM | 1.0 ug DNA | EUR 486 |
Psmb8 ORF Vector (Mouse) (pORF) |
|||
| ORF055097 | ABM | 1.0 ug DNA | EUR 607.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-100ul | Abclonal | 100 ul | EUR 492 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-200ul | Abclonal | 200 ul | EUR 685.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-20ul | Abclonal | 20 ul | EUR 265.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-50ul | Abclonal | 50 ul | EUR 344.4 |
PSMB8 ELISA Kit (Dog) (OKEH03975) |
|||
| OKEH03975 | Aviva Systems Biology | 96 Wells | EUR 1012.8 |
|
Description: Description of target: ;Species reactivity: Dog;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.064 ng/mL |
|||
PSMB8 ELISA Kit (Human) (OKEH07770) |
|||
| OKEH07770 | Aviva Systems Biology | 96 Wells | EUR 1310.4 |
|
Description: Description of target: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.06ng/mL |
|||
PSMB8 ELISA Kit (Human) (OKCD02695) |
|||
| OKCD02695 | Aviva Systems Biology | 96 Wells | EUR 950.4 |
|
Description: Description of target: The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.117 ng/mL |
|||
Psmb8 sgRNA CRISPR Lentivector set (Rat) |
|||
| K6921501 | ABM | 3 x 1.0 ug | EUR 406.8 |
PSMB8 sgRNA CRISPR Lentivector set (Human) |
|||
| K1740301 | ABM | 3 x 1.0 ug | EUR 406.8 |
Psmb8 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K4425601 | ABM | 3 x 1.0 ug | EUR 406.8 |
Psmb8 3'UTR GFP Stable Cell Line |
|||
| TU167173 | ABM | 1.0 ml | Ask for price |
PSMB8 3'UTR GFP Stable Cell Line |
|||
| TU069046 | ABM | 1.0 ml | EUR 1672.8 |
Psmb8 3'UTR GFP Stable Cell Line |
|||
| TU266964 | ABM | 1.0 ml | Ask for price |
PSMB8 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV296844 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPB-C-His) |
|||
| PV296842 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPB-N-His) |
|||
| PV296843 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPM-C-His) |
|||
| PV296845 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Human) (pPM-C-HA) |
|||
| PV113812 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV220388 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Human) (pPB-C-His) |
|||
| PV113810 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPB-N-His) |
|||
| PV113811 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPM-C-His) |
|||
| PV113813 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV220386 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV220387 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV220389 | ABM | 500 ng | EUR 723.6 |
Psmb8 3'UTR Luciferase Stable Cell Line |
|||
| TU117173 | ABM | 1.0 ml | Ask for price |
PSMB8 3'UTR Luciferase Stable Cell Line |
|||
| TU019046 | ABM | 1.0 ml | EUR 1672.8 |
Psmb8 3'UTR Luciferase Stable Cell Line |
|||
| TU216964 | ABM | 1.0 ml | Ask for price |
Human Proteasome subunit beta type-8 (PSMB8) |
|||
| 1-CSB-EP018886HU | Cusabio |
|
|
|
Description: Recombinant Human Proteasome subunit beta type-8(PSMB8) expressed in E.coli |
|||
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6921502 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6921503 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6921504 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K1740302 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K1740303 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K1740304 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K4425602 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K4425603 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K4425604 | ABM | 1.0 ug DNA | EUR 184.8 |
Recombinant Human PSMB8 Protein, His, E.coli-1mg |
|||
| QP13190-1mg | EnQuireBio | 1mg | EUR 3308.4 |
Recombinant Human PSMB8 Protein, His, E.coli-5ug |
|||
| QP13190-5ug | EnQuireBio | 5ug | EUR 186 |
Recombinant Human PSMB8 Protein, His, E.coli-20ug |
|||
| QP13190-20ug | EnQuireBio | 20ug | EUR 241.2 |
PSMB8 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV700471 | ABM | 1.0 ug DNA | EUR 616.8 |
PSMB8 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV700475 | ABM | 1.0 ug DNA | EUR 616.8 |
PSMB8 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV700476 | ABM | 1.0 ug DNA | EUR 616.8 |
PSMB10 antibody |
|||
| 38658-100ul | SAB | 100ul | EUR 302.4 |
PSMB10 antibody |
|||
| 70R-5872 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal PSMB10 antibody |
|||
PSMB10 antibody |
|||
| 70R-19581 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal PSMB10 antibody |
|||
PSMB11 antibody |
|||
| 70R-19582 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal PSMB11 antibody |
|||
PSMB10 Antibody |
|||
| DF14390 | Affbiotech | 100ul | EUR 420 |
Integration of genetic counsellors in genomic testing triage: Outcomes of a Genomic Consultation Service in British Columbia, Canada
Purpose: Clinical diagnostic genome-wide (exome or genome) sequencing (GWS) in British Columbia requires funding approval by a provincial agency on a case-by-case basis. The CAUSES Clinic was a pediatric translational trio-based GWS study at BC Children’s and Women’s Hospitals.
Referrals to the CAUSES Clinic were made through a Genomic Consultation Service (GCS), a multidisciplinary team led by genetic counsellors that provided advice regarding genomic testing for physicians considering GWS for their patients.
Here we review the outcomes of the GCS, focusing on patients not recommended for the CAUSES Study.
Methods: Demographic, clinical, and testing data were abstracted from patient charts. Logistic regression analysis was used to explore associations between demographic and clinical variables and two outcomes: the type of recommendation and referring physicians’ decisions to follow the recommendation.
Results: Of 972 GCS referrals, 248 patients were not referred to the CAUSES Study. GWS (vs. a targeted test; e.g. multi-gene panel) was more likely to be recommended to physicians of patients with ID than physicians of patients without ID (OR = 2.98; 95% CI = 1.46 to 6.27; n = 149). In total, 40% of physicians who were recommended to pursue clinical genomic testing submitted an application for funding approval; 71% of applications were approved for funding. Among approved tests, 50% resulted in a diagnosis, including 33% of targeted tests and 82% of GWS tests (χ2 (1) = 5.0, p = 0.026).
Conclusion: The GCS provided an effective model in which physicians can interface with genetic specialists, including genetic counsellors, to facilitate appropriate genomic test selection.
From Probands to Relatives: Communication of Genetic Risk for Hereditary Breast-Ovarian Cancer and Its Influence on Subsequent Testing
Background: The genetic risk communication from proband to relatives varies from family to family, and patients often need support with the communication of genetic test results and making decisions to manage hereditary cancer risks.
Objective: The aim of this study was to characterize the communication of BRCA1 or BRCA2 (BRCA1/2) genetic risk from proband to first-degree relatives (FDRs) using a social network framework.
Methods: We characterized network and nonnetwork factors to explore their association with which FDRs were told about the genetic risk and whether or not relatives underwent genetic testing. Ninety-two female probands with hereditary breast and ovarian cancer who have confirmed BRCA1/2 mutations participated in the study. Communication of hereditary breast and ovarian cancer risk was assessed between 92 probands and their 417 FDRs.
Results: Of 92 probands, 94.5% (n = 87) communicated their genetic test result to at least one of their FDRs. Of FDRs older than 18 years, 19.9% (n = 72) have genetic testing. Emotional closeness, educational level of the proband, and relative’s age were significantly associated with communicating test results with FDRs.
Conclusion: Communication of genetic risk with the FDRs after having a BRCA1/2 gene-mutation-positive test result was high in this group of cancer patients. However, the rate of genetic testing among FDRs was low.
Implications for practice: Probands’ educational level and age of relatives for cascade genetic screening should be considered during counseling. Interventions to support women with BRCA1/2 mutations during the communication process and their family members’ engagement in testing and risk-reducing strategies are needed.
PSMB8 Polyclonal Antibody |
|||
| A73468 | EpiGentek |
|
|
PSMB8 Antibody, HRP conjugated |
|||
| 1-CSB-PA018886LB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
PSMB8 Antibody, FITC conjugated |
|||
| 1-CSB-PA018886LC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
PSMB8 Antibody, Biotin conjugated |
|||
| 1-CSB-PA018886LD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
Monoclonal PSMB8 Antibody, Clone: 1A5 |
|||
| AMM02864G | Leading Biology | 0.1ml | EUR 633.6 |
|
Description: A Monoclonal antibody against Human PSMB8. The antibodies are raised in Mouse and are from clone 1A5. This antibody is applicable in WB and IHC, ICC, E |
|||
Psmb8/ Rat Psmb8 ELISA Kit |
|||
| ELI-15652r | Lifescience Market | 96 Tests | EUR 1063.2 |
Proteasome subunit beta type-8 (PSMB8) Antibody |
|||
| 20-abx211178 | Abbexa |
|
|
Proteasome subunit beta type-8 (PSMB8) Antibody |
|||
| 20-abx211851 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx141396 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx114776 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx028154-400ul | Abbexa | 400 ul | EUR 627.6 |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx028154-80l | Abbexa | 80 µl | EUR 343.2 |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| 20-abx006453 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
| abx011689-100ul | Abbexa | 100 ul | EUR 493.2 |
Monoclonal PSMB8 Antibody (monoclonal) (M01), Clone: 1B3 |
|||
| AMM03954G | Leading Biology | 0.1mg | EUR 580.8 |
|
Description: A Monoclonal antibody against Human PSMB8 (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 1B3. This antibody is applicable in WB, IHC and IF, IP, E |
|||
PSMB8 siRNA |
|||
| 20-abx930156 | Abbexa |
|
|
PSMB8 siRNA |
|||
| 20-abx930157 | Abbexa |
|
|
PSMB8 siRNA |
|||
| 20-abx904317 | Abbexa |
|
|
PSMB8 Rabbit pAb |
|||
| A7340-100ul | Abclonal | 100 ul | EUR 369.6 |
PSMB8 Rabbit pAb |
|||
| A7340-200ul | Abclonal | 200 ul | EUR 550.8 |
PSMB8 Rabbit pAb |
|||
| A7340-20ul | Abclonal | 20 ul | EUR 219.6 |
PSMB8 Rabbit pAb |
|||
| A7340-50ul | Abclonal | 50 ul | EUR 267.6 |
PSMB8 Blocking Peptide |
|||
| BF0434-BP | Affbiotech | 1mg | EUR 234 |
PSMB8 protein (His tag) |
|||
| 80R-2608 | Fitzgerald | 100 ug | EUR 386.4 |
|
Description: Purified recombinant PSMB8 protein |
|||
Canine PSMB8 ELISA KIT |
|||
| ELI-15651d | Lifescience Market | 96 Tests | EUR 1113.6 |
Rat PSMB8 shRNA Plasmid |
|||
| 20-abx984734 | Abbexa |
|
|
Human PSMB8 shRNA Plasmid |
|||
| 20-abx953843 | Abbexa |
|
|
Mouse PSMB8 shRNA Plasmid |
|||
| 20-abx971337 | Abbexa |
|
|
PSMB8 Recombinant Protein (Rat) |
|||
| RP222629 | ABM | 100 ug | Ask for price |
PSMB8 Recombinant Protein (Mouse) |
|||
| RP165287 | ABM | 100 ug | Ask for price |
PSMB8 Recombinant Protein (Human) |
|||
| RP085356 | ABM | 100 ug | Ask for price |
Psmb8 ORF Vector (Rat) (pORF) |
|||
| ORF074211 | ABM | 1.0 ug DNA | EUR 607.2 |
PSMB8 ORF Vector (Human) (pORF) |
|||
| ORF028453 | ABM | 1.0 ug DNA | EUR 486 |
Psmb8 ORF Vector (Mouse) (pORF) |
|||
| ORF055097 | ABM | 1.0 ug DNA | EUR 607.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-100ul | Abclonal | 100 ul | EUR 492 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-200ul | Abclonal | 200 ul | EUR 685.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-20ul | Abclonal | 20 ul | EUR 265.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
| A19933-50ul | Abclonal | 50 ul | EUR 344.4 |
PSMB8 ELISA Kit (Dog) (OKEH03975) |
|||
| OKEH03975 | Aviva Systems Biology | 96 Wells | EUR 1012.8 |
|
Description: Description of target: ;Species reactivity: Dog;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.064 ng/mL |
|||
PSMB8 ELISA Kit (Human) (OKEH07770) |
|||
| OKEH07770 | Aviva Systems Biology | 96 Wells | EUR 1310.4 |
|
Description: Description of target: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.06ng/mL |
|||
PSMB8 ELISA Kit (Human) (OKCD02695) |
|||
| OKCD02695 | Aviva Systems Biology | 96 Wells | EUR 950.4 |
|
Description: Description of target: The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.117 ng/mL |
|||
Psmb8 sgRNA CRISPR Lentivector set (Rat) |
|||
| K6921501 | ABM | 3 x 1.0 ug | EUR 406.8 |
PSMB8 sgRNA CRISPR Lentivector set (Human) |
|||
| K1740301 | ABM | 3 x 1.0 ug | EUR 406.8 |
Psmb8 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K4425601 | ABM | 3 x 1.0 ug | EUR 406.8 |
Psmb8 3'UTR GFP Stable Cell Line |
|||
| TU167173 | ABM | 1.0 ml | Ask for price |
PSMB8 3'UTR GFP Stable Cell Line |
|||
| TU069046 | ABM | 1.0 ml | EUR 1672.8 |
Psmb8 3'UTR GFP Stable Cell Line |
|||
| TU266964 | ABM | 1.0 ml | Ask for price |
PSMB8 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV296844 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPB-C-His) |
|||
| PV296842 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPB-N-His) |
|||
| PV296843 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPM-C-His) |
|||
| PV296845 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Human) (pPM-C-HA) |
|||
| PV113812 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV220388 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Human) (pPB-C-His) |
|||
| PV113810 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPB-N-His) |
|||
| PV113811 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPM-C-His) |
|||
| PV113813 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV220386 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV220387 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV220389 | ABM | 500 ng | EUR 723.6 |
Psmb8 3'UTR Luciferase Stable Cell Line |
|||
| TU117173 | ABM | 1.0 ml | Ask for price |
PSMB8 3'UTR Luciferase Stable Cell Line |
|||
| TU019046 | ABM | 1.0 ml | EUR 1672.8 |
Psmb8 3'UTR Luciferase Stable Cell Line |
|||
| TU216964 | ABM | 1.0 ml | Ask for price |
Human Proteasome subunit beta type-8 (PSMB8) |
|||
| 1-CSB-EP018886HU | Cusabio |
|
|
|
Description: Recombinant Human Proteasome subunit beta type-8(PSMB8) expressed in E.coli |
|||
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6921502 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6921503 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6921504 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K1740302 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K1740303 | ABM | 1.0 ug DNA | EUR 184.8 |
PSMB8 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K1740304 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K4425602 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K4425603 | ABM | 1.0 ug DNA | EUR 184.8 |
Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K4425604 | ABM | 1.0 ug DNA | EUR 184.8 |
Recombinant Human PSMB8 Protein, His, E.coli-1mg |
|||
| QP13190-1mg | EnQuireBio | 1mg | EUR 3308.4 |
Recombinant Human PSMB8 Protein, His, E.coli-5ug |
|||
| QP13190-5ug | EnQuireBio | 5ug | EUR 186 |
Recombinant Human PSMB8 Protein, His, E.coli-20ug |
|||
| QP13190-20ug | EnQuireBio | 20ug | EUR 241.2 |
PSMB8 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV700471 | ABM | 1.0 ug DNA | EUR 616.8 |
PSMB8 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV700475 | ABM | 1.0 ug DNA | EUR 616.8 |
PSMB8 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV700476 | ABM | 1.0 ug DNA | EUR 616.8 |
PSMB10 antibody |
|||
| 38658-100ul | SAB | 100ul | EUR 302.4 |
PSMB10 antibody |
|||
| 70R-5872 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal PSMB10 antibody |
|||
PSMB10 antibody |
|||
| 70R-19581 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal PSMB10 antibody |
|||
PSMB11 antibody |
|||
| 70R-19582 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal PSMB11 antibody |
|||
PSMB10 Antibody |
|||
| DF14390 | Affbiotech | 100ul | EUR 420 |
PSMB10 Antibody |
|||
| 1-CSB-PA018877ESR1HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB10. Recognizes PSMB10 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
PSMB10 Antibody |
|||
| 1-CSB-PA018877GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB10. Recognizes PSMB10 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
|||
PSMB11 Antibody |
|||
| 1-CSB-PA018878GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against PSMB11. Recognizes PSMB11 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
|||
PSMB10 Antibody |
|||
| R35169-100UG | NSJ Bioreagents | 100 ug | EUR 339.15 |
|
Description: Additional name(s) for this target protein: Proteasome (prosome, macropain) subunit, beta type, 10 |
|||